Nav: Home

Combining NSAIDs and TNFi may reduce radiographic progression in ankylosing spondylitis

June 14, 2018

The results of a cohort study presented at the Annual European Congress of Rheumatology (EULAR 2018) showed that, in patients with ankylosing spondylitis (AS) taking tumour necrosis factor (TNF) inhibitors, the addition of non-steroidal anti-inflammatory drugs (NSAIDs) was associated with significantly less radiographic progression in a dose-related manner at four years.1

When looking at specific NSAIDs, celecoxib in combination with TNF inhibitor use was associated with the greatest reduction in radiographic progression, which was significant at both two and four years.1

"Our results suggest that the use of TNF inhibitors and NSAIDs, particularly celecoxib, have a synergistic effect to slow radiographic progression in AS patients, particularly at higher doses," said Lianne Gensler, Associate Professor of Medicine, University of California, San Francisco (study author). "This is the first study to compare whether effects are comparable among different NSAIDs in this setting."

Ankylosing spondylitis is a chronic inflammatory disease that can be classified as being axial or non-axial (peripheral) disease, according to which joints in their body are affected. Over time, the joints can become damaged, a process referred to as radiographic or structural progression.

NSAIDs are first-line therapy for patients with AS. If patients have a poor response, contraindications or intolerance to NSAIDs, they may then be given TNF inhibitors.2 Current treatment practice is based on symptomatic relief, however there is also some evidence that NSAIDs slow radiographic progression if taken continuously.3 The evidence for the impact of TNF inhibitors on radiographic progression is unclear despite their good clinical efficacy.4,5 Many patients discontinue NSAIDs when they are put onto TNF inhibitors due to good symptom control,6 therefore there is very limited data on the impact of combined therapy on radiographic progression.

"Radiographic progression has an important bearing on patient mobility, as well as affecting their general well-being and day-to-day living," said Professor Robert Landewé, Chairperson of the Scientific Programme Committee, EULAR. "We welcome these results that support a potential disease modifying effect in patients with ankylosing spondylitis taking current therapies."

This prospective cohort study included 519 patients with AS who met the modified New York criteria with at least four years of clinical and radiographic follow up. The average age of participants was 41.4 years with an average symptom duration of 16.8 years, three quarters were male. NSAIDs were used in 66% of patients (half using an index below 50 and half above). TNF inhibitors were used in 46% of patients.1

After baseline measures, clinical and medication data were collected every six months, and radiographs performed every two years. Radiographic progression was measured using the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS). Statistical analysis which accounted for time-varying covariates was used to estimate the causal effect of TNF inhibitors and NSAIDs on radiographic progression. The analysis was adjusted for gender, race/ethnicity, education, symptom duration, enrolment year, number of years on TNF inhibitors, symptom duration at time of TNF inhibitor start, baseline mSASSS, ASDAS-CRP*, current smoking, and missed visit status.1

In patients taking TNFi, the addition of NSAID therapy was associated with less radiographic progression in a dose-related manner at four years. Mean difference in mSASSS between TNFi use and no TNFi use at four years was 0.50 (p=0.38), -1.24 (p<0.001), and -3.31 (p<0.001) for no NSAID, low NSAID, and high NSAID. When NSAID specific effects were examined, celecoxib in combination with TNFi use was associated with the greatest reduction in radiographic progression and this was significant at both two and four years. The mean difference in mSASSS between TNFi and no TNFi use for celecoxib was -3.98 (p<0.001) and -4.69 (p<0.001) at two and four years respectively.1
-end-
Abstract number: OP0198

* Ankylosing Spondylitis Disease Activity Score-C-reactive protein (ASDAS-CRP)

NOTES TO EDITORS

For further information on this study, or to request an interview with the study lead, please do not hesitate to contact the EULAR Press Office:

Email: eularpressoffice@ruderfinn.co.uk

Telephone: +44 (0) 20 7438 3084

Twitter: @EULAR_Press

YouTube: Eular Press Office

About Rheumatic and Musculoskeletal Diseases

Rheumatic and musculoskeletal diseases (RMDs) are a diverse group of diseases that commonly affect the joints but can affect any organ of the body. There are more than 200 different RMDs, affecting both children and adults. They are usually caused by problems of the immune system, inflammation, infections or gradual deterioration of joints, muscle and bones. Many of these diseases are long term and worsen over time. They are typically painful and Iimit function. In severe cases, RMDs can result in significant disability, having a major impact on both quality of life and life expectancy.7

About 'Don't Delay, Connect Today!'

'Don't Delay, Connect Today!' is a EULAR initiative that unites the voices of its three pillars, patient (PARE) organisations, scientific member societies and health professional associations - as well as its international network - with the goal of highlighting the importance of early diagnosis and access to treatment. In the European Union alone, over 120 million people are currently living with a rheumatic disease (RMD), with many cases undetected.8 The 'Don't Delay, Connect Today!' campaign aims to highlight that early diagnosis of RMDs and access to treatment can prevent further damage, and also reduce the burden on individual life and society as a whole.

About EULAR

The European League against Rheumatism (EULAR) is the European umbrella organisation representing scientific societies, health professional associations and organisations for people with RMDs. EULAR aims to reduce the burden of RMDs on individuals and society and to improve the treatment, prevention and rehabilitation of RMDs. To this end, EULAR fosters excellence in education and research in the field of rheumatology. It promotes the translation of research advances into daily care and fights for the recognition of the needs of people with RMDs by the EU institutions through advocacy action.

To find out more about the activities of EULAR, visit: http://www.eular.org.

References

1 Gensler LS, Gianfrancesco M, Weisman MH, et al. Combined effects of tumor necrosis factor inhibitors and NSAIDS on radiographic progression in ankylosing spondylitis. EULAR 2018; Amsterdam: Abstract OP0198.

2 van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978-991.

3 Wanders A, Heijde D, Landewe R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005;52:1756-65.

4 van der Heijde D, Landewé R, Baraliakos X, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum. 2008;58:3063-70.

5 Haroon N, Inman RD, Learch TJ, et al. The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2013;65:2645-2654.

6 Dougados M, Wood E, Combe B, et al. Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study. Arthritis Res Ther. 2014;16(6):481.

7 van der Heijde D, et al. Common language description of the term rheumatic and musculoskeletal diseases (RMDs) for use in communication with the lay public, healthcare providers and other stakeholders endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR). Annals of the Rheumatic Diseases. 2018;doi:10.1136/annrheumdis-2017-212565. [Epub ahead of print].

8 EULAR. 10 things you should know about rheumatic diseases fact sheet. Available at: https://www.eular.org/myUploadData/files/10%20things%20on%20RD.pdf [Last accessed April 2018].

European League Against Rheumatism

Related Ankylosing Spondylitis Articles:

New medication guidelines for rheumatic disease patients having joint replacement
In the first such collaboration of its kind, an expert panel of rheumatologists and orthopedic surgeons has developed guidelines for the perioperative management of anti-rheumatic medication in patients undergoing total hip or knee replacement.
Low-dose CT scanning improves assessment of ankylosing spondylitis patients
The results of a study presented today at the Annual European Congress of Rheumatology 2017 showed that low dose computed tomography is more sensitive than conventional radiographs (X-rays) in the monitoring of disease progression in patients with Ankylosing Spondylitis (AS).
Cutting-edge analysis reveals how different drugs interact with the same target
Osaka University-led researchers identified differences in how three drugs bind to tumor necrosis factor, a key mediator of inflammatory disease.
Combination of NSAIDs and TNF-inhibitors shows benefit for ankylosing spondylitis
A combination of nonsteroidal anti-inflammatory drugs and TNF-inhibitors may help slow down spine damage in ankylosing spondylitis, according to new research findings presented this week at the American College of Rheumatology Annual Scientific Meeting in Washington.
Statins may lower mortality risk in ankylosing spondylitis and psoriatic arthritis patients
Patients with ankylosing spondylitis or psoriatic arthritis who take statins may have as much as a 33 percent lower mortality risk, according to new research findings presented this week at the American College of Rheumatology Annual Scientific Meeting in Washington.
Women & long-term axial spondyloarthropathy patients at higher risk for manifestations
Gender and disease duration can help predict which axial spondyloarthritis patients will develop extra-articular manifestations such as uveitis, or inflammation of the eye, according to new research findings presented this week at the 2016 ACR/ARHP Annual Meeting in Washington.
Study shows swimming is an effective part of the treatment for fibromyalgia
A study performed by researchers at the Federal University of São Paulo shows swimming is as effective as walking to relieve pain and improve quality of life for patients with fibromyalgia, that experience chronic diffuse non-inflammatory pain in the musculoskeletal system deriving from malfunctioning of the system that transmits and modulates the transmission of nervous stimuli between the periphery of the body and the brain.
Facebook key to identifying thousands with inflammatory back pain
Facebook key to identifying thousands with inflammatory back pain.
Secukinumab in ankylosing spondylitis or psoriatic arthritis: Added benefit not proven
Drug manufacturer presented no relevant data and claimed no added benefit.
Global study reveals genes as major cause of inflammatory diseases
A world-first study led by Australia's Queensland University of Technology and Germany's Christian-Albrechts-University is likely to result in new treatments for five common and painful inflammatory diseases that affect millions of people around the world.

Related Ankylosing Spondylitis Reading:

Beating Ankylosing Spondylitis Naturally
by Dr. Scott A Johnson (Author)

An essential guide for AS patients, their loved ones, and physicians who want to discover the research and evidence-based natural options to beat ankylosing spondylitis naturally. Explore the intricacies of ankylosing spondylitis and how it affects the body with someone who actually has AS—bestselling author, naturopath, and natural health expert Dr. Scott A. Johnson. ~ Learn the connection linking AS, eating, and gut health and how being armed with this knowledge may help you reduce AS symptoms. ~ Examine evidence-based natural remedies to quiet inflammation, soothe pain, and manage the... View Details


The Keystone Approach: Healing Arthritis and Psoriasis by Restoring the Microbiome
by Rebecca Fett (Author)

The Keystone Approach is based on a profound shift in our understanding of the causes of autoimmune disease. Specifically, a series of groundbreaking new clinical studies have found that autoimmunity is often driven by the immune system overreacting to certain gut bacteria. This overreaction is caused by a more permeable gut barrier, the overgrowth of pathogenic gut bacteria or yeasts, and the lack of beneficial immune-calming microbes.  
This innovative new book provides a systematic, evidence-based plan to address each of these elements, from the perspective of a science... View Details


Ankylosing Spondylitis
by Michael H. Weisman (Author)

Ankylosing Spondylitis is an inflammatory arthritis that affects the spine and sacroiliac joints as well as other parts of the body, and that can eventually lead, in some patients, to complete fusion of the vertebrae and total rigidity. AS is not a rare health problem, but is in fact found in almost one percent of the US population, typically strikes young people and young families, and in its various forms is probably more common than rheumatoid arthritis.
In this invaluable guide, Dr. Michael H. Weisman, one of America's leading authorities on AS, provides a down-to-earth,... View Details


Ankylosing Spondylitis: THE CURE
by ELEMENT 34

INTRODUCTION :
Thanks to an antibiotic, I am cured of ankylosing spondylitis. I feel it my duty to convey my experience to all sufferers of this extremely painful and debilitating disease.
In this book, I will also disclose my personal medical record (Rheumatology, radiology, MRI, medical biology laboratory) stating that I had ankylosing spondylitis and that I recovered.
My annual radiography checks show that the disease has once and for all stopped its destructive inflammation of the joints. For years I have had no pain and I have regained full mobility.
My rheumatologist... View Details


Ankylosing Spondylitis: The Facts (The Facts Series)
by Muhammad Asim Khan (Author)

Ankylosing spondilitis is a chronic form of arthritis known to affect around 1 in 200 people (over 1 million sufferers in the USA alone). No cure has yet been found for the disease, however, early diagnosis and proper medical management can be important in reducing the risk of disability and deformity. Ankylosing spondilitis: the facts is the first mass market book to be published on this important disease. It provides clear and accessible information on treatment, diagnosis, genetic counselling, and daily life with this illness. Professor Khan is one of the leading experts in the world on... View Details


Ankylosing spondylitis e-chart: Quick reference guide

Ankylosing spondylitis e-chart - Quick reference guide
Ankylosing spondylitis
Clinical Features
Diagnostic criteria
Schematic view of the progression of ankylosing spondylitis
Lateral view
Anteroposterior view
Sites of inflammation
Normal Anatomy
Sacroiliitis with fusion of lumbar and coxofemoral joints
Cervical Spine
Thoracic Spine
Lumbar Spine
Recommendations for patients


View Details


Ankylosing Spondylitis Pyramid: The Lifestyle That Lets You Take Back Control
by Michael W. Smith, MD

The best treatment for ankylosing spondylitis is medicine, right? Many doctors would agree. That’s where traditional medicine has done a disservice to all of us living with AS. You need to focus on what you can do to help your AS – not what your doctor can do. If you make medicine your top priority, you’ve lost the battle.

As a physician and patient with ankylosing spondylitis for more than 30 years, Michael W. Smith, MD is in a unique position. Too many patients with AS focus their energy on the wrong things. That’s what drove Dr. Smith to develop the Ankylosing... View Details


Ankylosing Spondylitis (Oxford American Rheumatology Library)
by Muhammad Asim Khan (Author)

Ankylosing Spondylitis (AS) and related diseases called spondyloarthropathies (SpA) are the second most common form of chronic inflammatory arthritis after Rheumatoid Arthritis (RA). Unfortunately, most patients with AS and SpA are either never diagnosed, or they are inadequately treated. The current mean delay in the diagnosis of AS ranges from 5 to 10 years, and the presenting clinical manifestations of these diseases are wide-ranging and heterogeneous, and thus a variety of health care professionals see AS and SpA patients, from primary care physicians to rheumatologists and other medical... View Details


The Ankylosing Spondylitis Cookbook

This is a cookbook for those living with Ankylosing Spondylitis. With this cookbook you will find the A.S. Diet far easier to follow and still be able to enjoy great food! The A.S. Diet is more decadent, rich, and satisfying than most so-called "healthy" diets. Gluten-free and "Paleo" by default, with the A.S. Cookbook at your side you can eat in ways you never dreamed while greatly reducing pain and inflammation from your Ankylosing Spondylitis or even other forms of arthritis. Many achieve a more healthy weight, too, without even trying! View Details


Kicking My AS: Life and Lessons of Ankylosing Spondylitis
by Kip Jennings (Author)

At 8:12 on a sunny, September morning my doctor's assistant called. "How far are you away from a hospital?" she asked. And so began what would ultimately be my life with Ankylosing Spondylitis, also known as AS... AS literally impacts millions of American lives, yet is a disease very few people have heard of, let alone understand. Mention "cancer" to someone and they inevitably say, "Oh!" Say ”Ankylosing Spondylitis” to that same person and they'll say, “Huh?” While the lack of knowledge of AS is understandable, it leads to misunderstandings and, ultimately, frustrations for not only... View Details

Best Science Podcasts 2018

We have hand picked the best science podcasts for 2018. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

The Person You Become
Over the course of our lives, we shed parts of our old selves, embrace new ones, and redefine who we are. This hour, TED speakers explore ideas about the experiences that shape the person we become. Guests include aerobatics pilot and public speaker Janine Shepherd, writers Roxane Gay and Taiye Selasi, activist Jackson Bird, and fashion executive Kaustav Dey.
Now Playing: Science for the People

#479 Garden of Marvels (Rebroadcast)
This week we're learning about botany and the colorful science of gardening. Author Ruth Kassinger joins us to discuss her book "A Garden of Marvels: How We Discovered that Flowers Have Sex, Leaves Eat Air, and Other Secrets of the Way Plants Work." And we'll speak to NASA researcher Gioia Massa about her work to solve the technical challenges of gardening in space.